14.02
-0.34 (-2.37%)
| Penutupan Terdahulu | 14.36 |
| Buka | 14.80 |
| Jumlah Dagangan | 1,227,836 |
| Purata Dagangan (3B) | 233,411 |
| Modal Pasaran | 1,860,269,696 |
| Harga / Jualan (P/S) | 28.50 |
| Harga / Buku (P/B) | 3.26 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2026 |
| Margin Operasi (TTM) | -633.21% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.34% |
| Nisbah Semasa (MRQ) | 0.960 |
| Aliran Tunai Operasi (OCF TTM) | -42.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.46 M |
| Pulangan Atas Aset (ROA TTM) | -4.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mesoblast Limited | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.06% |
| % Dimiliki oleh Institusi | 3.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Arax Advisory Partners | 31 Dec 2025 | 166,482 |
| Penbrook Management Llc | 31 Dec 2025 | 87,575 |
| Prosperity Wealth Management, Inc. | 30 Sep 2025 | 49,950 |
| Rialto Wealth Management, Llc | 31 Dec 2025 | 46,500 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Ryoncil® Net Revenues Increase for the Quarter to US$30M |
| 26 Jan 2026 | Pengumuman | Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment |
| 18 Jan 2026 | Pengumuman | FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy |
| 08 Jan 2026 | Pengumuman | Ryoncil® Sales Increase 60% in December Quarter to US$35.1M |
| 01 Jan 2026 | Pengumuman | Mesoblast Announces Changes to Board of Directors' Leadership Roles |
| 29 Dec 2025 | Pengumuman | Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |